GEN 0101

Drug Profile

GEN 0101

Alternative Names: GEN0101; HVJ-E; TSD-0014

Latest Information Update: 20 Oct 2015

Price : $50

At a glance

  • Originator GenomIdea
  • Developer GenomIdea; Ishihara Sangyo Kaisha; Osaka University Hospital; TSD Japan
  • Class Antineoplastics; Viral envelope proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Mesothelioma; Prostate cancer

Most Recent Events

  • 14 Oct 2015 Phase-I clinical trials in Mesothelioma (Treatment-resistant) in Japan (SC) (UMIN000019345)
  • 14 Oct 2015 Phase-I clinical trials in Mesothelioma (Treatment-resistant) in Japan (Intratumoural) (UMIN000019345)
  • 01 Jun 2015 Phase-I clinical trials in Prostate cancer in Japan (Parenteral) (UMIN000017092)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top